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Abstract
Background: Rheumatoid arthritis is a common autoimmune disorder influenced by both genetic and
environmental factors. Epigenome-wide association studies can identify environmentally mediated epigenetic
changes such as altered DNA methylation, which may also be influenced by genetic factors. To investigate possible
contributions of DNA methylation to the aetiology of rheumatoid arthritis with minimum confounding genetic
heterogeneity, we investigated genome-wide DNA methylation in disease-discordant monozygotic twin pairs.
Methods: Genome-wide DNA methylation was assessed in 79 monozygotic twin pairs discordant for rheumatoid
arthritis using the HumanMethylation450 BeadChip array (Illumina). Discordant twins were tested for both differential
DNA methylation and methylation variability between rheumatoid arthritis and healthy twins. The methylation
variability signature was then compared with methylation variants from studies of other autoimmune diseases and
with an independent healthy population.
Results: We have identified a differentially variable DNA methylation signature that suggests multiple stress response
pathways may be involved in the aetiology of the disease. This methylation variability signature also highlighted
potential epigenetic disruption of multiple RUNX3 transcription factor binding sites as being associated with disease
development. Comparison with previously performed epigenome-wide association studies of rheumatoid arthritis and
type 1 diabetes identified shared pathways for autoimmune disorders, suggesting that epigenetics plays a role in
autoimmunity and offering the possibility of identifying new targets for intervention.
Conclusions: Through genome-wide analysis of DNA methylation in disease-discordant monozygotic twins, we have
identified a differentially variable DNA methylation signature, in the absence of differential methylation in rheumatoid
arthritis. This finding supports the importance of epigenetic variability as an emerging component in autoimmune
disorders.
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Background
Low disease concordance rates between monozygotic
(MZ) twins (~ 15%) have revealed that environmental
exposures are important in rheumatoid arthritis (RA)
[1]. Many putative environmental risk factors have been
investigated, including exposure to cigarette smoke,
hormone influences, infection, vitamin D intake and diet-
ary factors [2, 3], but few have been robustly confirmed.
Epigenetics is the study of heritable modifications of
DNA which can alter gene expression without changing
the DNA sequence and which can be influenced by en-
vironmental factors, such as smoking [4]. The most
widely studied epigenetic phenomenon is DNA methyla-
tion, which may act as a composite measure of numer-
ous environmental exposures, making it an intriguing
candidate for investigation of diseases that involve both
genetic and environmental factors, such as RA.
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Current evidence suggests that DNA methylation
changes are associated with RA [5–10] but whether this
is due to intrinsic genetic differences, which can also in-
fluence DNA methylation, is not yet known. Disease-
discordant MZ twin pairs offer an ideal study design as
they are matched for many factors, including genetic
variation and as such they offer a crucial advantage in
epigenetic studies [11]. Differences in methylation be-
tween MZ twins may capture the effects of environmen-
tally driven mechanisms, independent of genetically
driven changes. Two small epigenome-wide association
studies (EWAS) of DNA methylation in MZ twins dis-
cordant for RA have reported conflicting results. The
first (n = 5 pairs) identifying no significant changes asso-
ciated with RA using the GoldenGate assay [12], while
the second (n = 7 pairs) identified no significant differen-
tially methylated positions (DMPs), but one significantly
differentially methylated region (DMR) using the
CHARM platform [13]. Due to the small sample sizes of
both studies, they were underpowered to detect subtle
methylation differences [14] and have limited scope to
characterise the epigenomic landscape of RA-discordant
twins.
To our knowledge, all studies of DNA methylation in
relation to RA have focussed on the identification of
DMPs or DMRs, which describe differential DNA
methylation levels at a particular CpG site or closely
spaced group of CpG sites, respectively. In DMPs and
DMRs, one group has a consistently higher level of
DNA methylation than the comparison group (e.g. when
comparing RA patients with healthy controls). Differen-
tially variable positions (DVPs) are another type of epi-
genetic variation, the importance of which has recently
been elucidated in type 1 diabetes (T1D) and cervical
and breast cancer [15–18]. DVPs are CpG sites that do
not necessarily have a large difference in mean DNA
methylation and therefore may not be classed as DMPs;
however, they have a difference in the range of DNA
methylation values between comparison groups.
We have examined genome-wide DNA methylation in
both a DMP and DVP context using the Infinium
HumanMethylation450 BeadChip array (Illumina) in
whole blood from 79 MZ twin pairs discordant for RA
from two independent cohorts (Manchester and Twin-
sUK, see Fig. 1). We identified a DVP signature in the
absence of a DMP signature that suggest potential roles
for multiple stress response pathways and potential epi-
genetic disruption of RUNX3 transcription factor bind-
ing sites in RA aetiology. We also identified shared
DVPs in both RA and T1D, indicating potential shared
pathways for autoimmune disorders.
Methods
TwinsUK participants
Twin pairs discordant for RA were identified from the
TwinsUK register [19]. RA status was assessed through
questionnaires between 1997 and 2002. In addition, an
advertisement was published in the National Rheuma-
toid Arthritis Society newsletter in spring 2013 to recruit
twin volunteers with RA. All MZ twins who answered
positively were phone-interviewed by a rheumatology
clinical fellow to confirm the diagnosis of RA based on
the American College of Rheumatology 1987 criteria (n
= 17 RA twins). In case of unclear diagnosis of RA, par-
ticipants were reviewed in clinic or were excluded. In
addition, all patients willing to attend a visit were exam-
ined clinically (n = 11 RA twins) by a clinical fellow
under the supervision of a consultant rheumatologist.
Visits included detailed medical history, review of symp-
toms, past and present medication (NSAIDS, disease-
modifying anti-rheumatic drugs (DMARDS) and/or bio-
logical agents) and joint examination. Blood samples
were collected from all subjects, from which DNA and
serum were extracted and stored at − 80 °C.
Fig. 1 Overview of study design. Rheumatoid arthritis-discordant twin pairs were recruited from the RA twins study in Manchester and TwinsUK
in London, and genome-wide DNA methylation was investigated in the context of both differentially methylated positions and differentially
variable positions
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The healthy co-twins were also reviewed at the clinical
visit. Non-RA status was supported by both clinical and
immunological details, as all non-RA twins were sero-
negative, except one who was rheumatoid factor (RF)
positive but clinically unaffected.
Manchester participants
Patients were selected from the Nationwide Rheumatoid
Arthritis Twin Study based at the University of Manches-
ter [1]. Twins were recruited in 1989 using a dual strategy:
(1) all UK rheumatologists were contacted and requested
to ask all of their patients with RA whether they were a
twin; (2) a multimedia campaign was targeted to patients
in whom RA had been diagnosed and who had a living
twin. Both members of each twin pair were visited at
home by trained research nurses who recorded each sub-
ject’s detailed medical history and demographic character-
istics and performed joint examinations. Blood samples
were collected from all subjects, from which DNA and
serum were extracted and stored at − 80 °C.
Measurement of genome-wide DNA methylation
For each sample, 500 ng DNA was bisulfite-converted
using EZ DNA methylation kits (ZYMO Research) ac-
cording to the manufacturer’s amended protocol for use
with the Infinium HumanMethylation450 BeadChip
(Illumina). Epigenome-wide methylation was assessed
using the Infinium HumanMethylation450 Assay (Illu-
mina) and the BeadChips were then imaged using the
Illumina iScan System.
Quality control and pre-processing of
HumanMethylation450 data
All data analysis was performed in R 3.4.1 (R Develop-
ment Core Team) using the minfi [20], ChAMP [21] and
CpGassoc packages [22]. Data quality for each sample was
assessed by visual inspection of kernel density plots of
methylation beta values and by comparing median log2
intensities recorded in both the methylated and unmethy-
lated channels. Probes which failed a detection p value of
0.01, probes mapping to the sex chromosomes, probes
containing a SNP within two base pairs of the measured
CpG site, cross reactive probes (according to Norlund,
2013) and probes with a bead count of < 3 in at least 5%
of samples were removed prior to analysis. Raw beta
values were logit transformed to M values following
subset-quantile within array normalisation (SWAN), and
principal component analysis (PCA) was performed to
capture any potential technical variation. Distinct cell pop-
ulations are known to have different DNA methylation
signatures [23]. Therefore, to assess if cell composition
differs between healthy and RA-affected twins, and
whether this may confound downstream analysis, we esti-
mated cell composition for each sample using the
reference-based Houseman method to infer relative pro-
portions of cells [24]. Differences in cell composition be-
tween groups were tested using a Welch two-sample t
test. Additionally, we applied the recently developed EpiD-
ISH algorithm to infer cell composition, which confirmed
the results obtained by Houseman’s algorithm (data not
shown) [25].
Identification of differentially methylated positions
(DMPs)
A mixed effects model was used to test for DMPs from
beta values using the CpGassoc package, adjusting for
sibling-pair effects as a random covariate. Factors associ-
ated with the first four principal components (PCs) were
included in the model as fixed covariates. False discovery
rate was calculated using the Benjamini and Hochberg
method [26], and a significance threshold of 0.05 was
used. Power to detect differential DNA methylation was
estimated using the calculations presented in [14], with
genome-wide significance threshold set to 1E−06 and
the false discovery rate controlled at 0.05.
Identification of differentially variable positions (DVPs)
Differential DNA methylation variability was tested in the
current study using the recently developed iEVORA algo-
rithm [16], which employs a modified version of Bartlett’s
test to test for differences in variability, in combination
with a standard t test to subsequently rank the identified
DVPs. A significance q value threshold of 0.001 was ap-
plied for the differential variability test, while a signifi-
cance p value threshold of 0.05 was applied for the
differential means.
Assessment of DVP signature in an independent healthy
population
In order to assess if the DVP signature identified be-
tween RA-discordant twins was present in an independ-
ent healthy cohort, methylation variability was assessed
in the BIOS cohort described in [27]. Briefly, this dataset
consisted of HumanMethylation450 profiles generated
from three Dutch cohorts, from which 156 profiles were
randomly selected to test methylation variability at the
DVP sites. The variance and range of methylation values
were calculated for each CpG site in the DVP signature,
stratified by directionality of variability in the signature
(i.e. if DVPs were hypervariable in healthy or RA twins).
Feature enrichment analysis
To investigate if DVPs identified in RA-discordant twins
were enriched in particular CpG island-associated fea-
tures, or in certain gene features, an enrichment analysis
was performed. All CpG sites included in analysis were
annotated using the HumanMethylation450 manifest.
Repeated random sampling (n = 1000) of all probes that
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passed quality control was used to assess enrichment of
features associated with DVPs [28].
Pathway analysis
Pathway analysis was performed within the MissMethyl
package [29] using the gometh function. Methylation ar-
rays have a significant bias in pathway analysis due to
the differential distribution of probes across different
genes [30]. For example, on the HumanMethylation450
BeadChip (Illumina), the number of probes on each gene
represented on the array ranges from 1 to 1299. Conse-
quently, during standard pathway analyses, genes with a
large number of probes present on the array are more
likely to be implicated in significant pathways. The Mis-
sMethyl package adjusts for such bias using a modified
hypergeometric test to test for over-representation of
the selected genes in each gene set. Pathways were
ranked by p value for over-representation of the gene
ontology terms (p < 0.05). False discovery rate (FDR) cor-
rection was not applied because biological pathways are
not independent from each other, and the FDR proced-
ure is only valid when tests are independent [26]. Add-
itionally, we performed gene set enrichment analysis
[31] on DVP-associated genes to corroborate top-ranked
pathways.
Overlap analyses
Using a meta-analysis approach, the DVPs from the
current study were compared with DVPs and DMPs
identified in previously performed large-scale EWAS of
various autoimmune disorders. Studies were selected
that had performed a site-specific genome-wide study of
DNA methylation (e.g. using methylation microarrays)
in an autoimmune disease, with at least 100 individuals
included in the study. The two qualifying studies fo-
cussed on T1D [15] in a discordant MZ twin approach,
and RA [7] in an unrelated case-control approach. Lists
of statistically significant DVPs (q < 0.001) and DMPs
(Bonferroni corrected p < 0.05) respectively reported in
each study were overlapped with DVPs identified in the
current study. This allowed identification of DVPs which




DNA samples from 79 MZ twin pairs discordant for RA
were available from the Nationwide Rheumatoid Arth-
ritis Twin Study (n = 62 twin pairs) and from the Twin-
sUK cohort (n = 17 twin pairs). Patient characteristics
are summarised in Table 1. There was no significant dif-
ference regarding smoking status between RA and
non-RA co-twins (p = 0.53). Of the RA co-twins in the
study, 59% were seropositive (anti-CCP and/or RF),
whereas 9% of the non-RA twins were RF positive. Of
the RA co-twins, 52% were taking disease-modifying
anti-rheumatic drugs (DMARDs) at the time of the
blood sampling, with the most prescribed being metho-
trexate (n = 9). Other commonly prescribed mono- or
bi-therapy DMARDs included penicillamine (n = 8), gold
(n = 8), sulphasalazine (n = 7) and hydroxychloroquine
(n = 5), reflecting the prescribing practices at the time
when the data was collected for the larger group of
twins. Treatment with DMARDs was not associated with
any of the top 20 principal components, and during as-
sessment with multidimensional scaling of the top 1000
most variable probes, treatment with DMARDs did not
separate out different groups (Additional file 1: Figure
S1); therefore, it was not adjusted for in the analysis.
This study had > 80% power to detect a mean methyla-
tion difference of 4% and 13% between the RA and
non-RA twins, at the 5% and genome-wide significance
threshold, respectively.
DMP analysis
Following stringent probe filtering, 430,780 probes were
available for further analyses in the dataset. Potential
confounding factors including gender, age, smoking
habits, cell composition, cohort, position on array and
BeadChip ID were all included as covariates in the linear
regression. None of the probes investigated were signifi-
cantly differentially methylated between the RA and
Table 1 Characteristics of the RA-discordant twin pairs
Characteristic RA (n = 79) Non-RA
(n = 79)
p value
*Age (years), mean (SD) 54.2 (12.2) 54.2 (12.2)
Female, n (%) 67 (86) 67 (86)
*Disease duration (years),
median (IQR)
9.8 (5.1, 17.2) –
Anti-CCP and/or RF
positive, n (%)
46 (59%) 7 (9%)
*DMARDs, n (%) 41 (52%) –
Smoking status 0.53
Current, n (%) 15(19) 12 (16)
Past, n (%) 26 (33) 22(28)
Never, n (%) 37(49) 44 (56)
**Cell type
CD8T 0.05 0.05 0.73
CD4T 0.24 0.19 0.16
Natural killer 0.06 0.06 0.99
B cell 0.06 0.05 0.61
Monocyte 0.08 0.07 0.15
Granulocyte 0.51 0.57 0.25
*At sampling
**Estimated from the DNA methylation data
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non-RA twins following correction for multiple testing,
using a false discovery rate threshold of 0.05. The mean
difference in methylation between RA-discordant twins
for the probes with the smallest adjusted p values (p >
0.13) was less than 4% (Table 2). To assess the influence
of differences in cell type composition on the epigenetic
profiles, we inferred differential cell type proportions
based on the DNA methylation data [24]. Proportions of
each cell type were compared between the two compari-
son groups, and there were no significant differences
(p > 0.15) in cellular composition between RA and
healthy co-twins (Table 1, Additional file 1: Figure S2).
Furthermore, adjustment for cell composition during
DMP detection did not affect the results qualitatively.
Rheumatoid arthritis associated DVPs
Variability of DNA methylation has been implicated in
T1D and cervical and breast cancer [15–17]. We used
the recently developed iEVORA algorithm [16] to test if
DNA methylation variability was significantly associated
with RA status between disease-discordant MZ twins. In
a group-wise test for differential variability between
RA-discordant MZ twins, 1171 DVPs were identified at
a stringent false discovery rate of < 0.001. An example of
the six top-ranked DVPs is shown in Fig. 2 and the an-
notation of the top 20 DVPs is summarised in Table 3
(full list of DVPs provided in Additional file 2: Table S1).
These DVPs were enriched in CpG sites that did not
map to CpG islands and were enriched in the body and
3′UTR of genes (Additional file 1: Figure S3).
Of the 1171 DVPs, 763 were hypervariable in the RA
twins, indicating an enrichment of methylation variability
in disease-affected individuals. DVPs that were hypervari-
able in RA twins were enriched in the 3′UTR of genes
and gene bodies, while DVPs that were hypervariable in
healthy twins were enriched in gene bodies (Fig. 3). The
underrepresentation of DVPs in CpG islands, particularly
in DVPs that were hypervariable in healthy twins, indi-
cates that these regions are more epigenetically stable. Of
the 763 DVPs which were hypervariable in RA twins, 563
showed a trend towards hypomethylation in the RA twins,
while of the 408 DVPs which were hypervariable in the
healthy twins, 401 showed a trend towards hypomethyla-
tion in the healthy twins. This finding indicates that
disease-associated methylation hypervariability is more
commonly associated with hypomethylation.
To investigate the DNA methylation variability of
RA-associated genes, DVPs were annotated and the gene
associated with each DVP was compared to RA-
associated genes identified during genetic studies.
Meta-analysis of RA susceptibility loci has previously
identified 98 genes associated with 101 genetic variants
Table 2 Top 20 differentially methylated positions between RA twins and non-RA twins. Probe names are shown, along with
methylation levels, intra-pair methylation difference, unadjusted p value and probe annotation
Probe Non-RA beta RA beta Diff p value Chr Relationship to gene Gene symbol
cg26547058 0.763 0.800 0.037 4.89E−07 8
cg07693617 0.758 0.788 0.030 5.15E−07 1 Body PRKCZ
cg07636225 0.849 0.867 0.018 9.33E−07 11 Body RTN3
cg03517226 0.709 0.716 0.007 1.18E−06 16 5′UTR ANKRD11
cg20666386 0.184 0.180 −0.004 1.89E−06 11 1stExon DGKZ
cg17501210 0.766 0.740 −0.026 2.54E−06 6 Body RPS6KA2
cg26964117 0.775 0.796 0.021 2.56E−06 19 Body PIH1D1
cg26701826 0.396 0.419 0.023 2.71E−06 4 5′UTR SGMS2
cg06040872 0.810 0.822 0.012 2.92E−06 17 Body CCL18
cg25487804 0.867 0.876 0.009 3.38E−06 11 TSS1500 OSBPL5
cg06128521 0.900 0.905 0.005 3.56E−06 17
cg16640599 0.421 0.447 0.026 3.58E−06 4 Body SEC24D
cg02445229 0.719 0.737 0.018 3.85E−06 19
cg01769457 0.039 0.043 0.004 3.90E−06 1
cg15293582 0.704 0.703 −0.001 4.06E−06 10 TSS1500 PRF1
cg07090025 0.091 0.100 0.009 4.21E−06 1 TSS200 SSU72
cg06791979 0.795 0.799 0.004 4.44E−06 11 Body RTN3
cg01934296 0.939 0.931 −0.008 4.45E−06 1 Body
cg26272088 0.819 0.838 0.019 4.54E−06 19 Body IRGC
cg18460107 0.674 0.679 0.005 4.71E−06 17 TSS200 SEPT9
Chr chromosome
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[32]. Of these 98 RA-associated genes, five contained at
least one DVP (CLNK, JAZF1, ICOSLG, NFKBIE and
BLK). JAZF1 contained two DVPs, both of which map to
the body of the gene. Further, when the 377 genes with
nominal association to RA from the same study were in-
vestigated, 15 genes contained at least one DVP. The
presence of genetic and epigenetic variants in the same
susceptibility genes indicates that disease-related changes
in gene function or expression could be implemented by
different mechanisms.
Functional annotation of the top ranked DVPs (ranked
by t-statistic p value) showed that the second and third
most highly ranked CpG sites (cg01999539 and
cg23280983) overlap with the binding site of the tran-
scription factor RUNX3. This differential variability of
DNA methylation could potentially be influencing the
binding of this transcription factor in multiple locations
throughout the genome. Several studies have implicated
RUNX3 in the development of immune-related diseases
including Crohn’s disease, ankylosing spondylitis, psoriasis
and ulcerative colitis (reviewed in [33]), and SNPs which
disrupt RUNX binding sites have also been associated with
RA [32, 34]. The disruption of the expression of RUNX3
transcription factors has also been found to alter the sup-
pressive function of regulatory T cells in human cells and
in mice, suggesting a potential functional consequence of
the methylation changes observed in RUNX3 binding sites
which warrants further investigation in RA [35].
Pathway analyses of rheumatoid arthritis-associated DVPs
Pathway analyses identified an enrichment of the
RA-associated DVPs in pathways (p < 0.05) involved in
response to cellular stress (Additional file 3: Table S2). A
pathway involving ubiquitination of the protein K63 was
also identified as enriched; this pathway has been found
to modulate oxidative stress response [36] which has a
role in RA pathogenesis [37]. When the pathway analysis
was restricted to DVPs which are hypervariable in non-RA
Fig. 2 CpG plots for six top ranked differentially variable positions in RA-discordant MZ twins. Cpg sites shown are cg11374732 (Bartlett’s test
p value = 4.09E−06), cg01999539, cg23280983, cg20500144, cg26985354 and cg26827503. Hypervariability of differentially variable positions was
enriched in RA twins. Boxplots indicating the mean methylation and range of methylation values are shown overlaid with scatterplots indicating
DNA methylation measurements of individual samples
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twins, there was an enrichment for immune-related
processes in the top-ranked pathways (Additional file 4:
Table S3). Two of the five top-ranked pathways were
related to T cell cytokine production, a critical process
in the development of RA.
Overlap with previously identified rheumatoid arthritis-
associated DMPs
Changes in DNA methylation have previously been associ-
ated with RA; however, these studies were performed in
unrelated case-control study designs. We hypothesised
Table 3 Top 20 differentially variable positions between RA-affected and non-RA twins. Probe names are shown, along with t-
statistic p value, Bartlett’s test for differential variability, which group was hypervariable, and probe annotation
Probe P(tt) P(BT) Hypervariable group Chr Relationship to gene Gene symbol
cg11374732 0.000513329 4.09E−06 RA 2 Body INPP5D
cg01999539 0.000614047 1.50E−05 RA 6
cg23280983 0.000689806 2.11E−05 RA 2 TSS200 C2orf42
cg20500144 0.000950244 6.82E−05 RA 3 Body ARL6IP5
cg26985354 0.001008386 2.18E−08 RA 19 Body SFRS16
cg26827503 0.001032395 2.68E−05 RA 4 Body TMEM156
cg11913894 0.001053694 2.93E−06 RA 6 TSS1500 MAP3K4
cg16583193 0.001125272 4.49E−06 RA 19 Body PIP5K1C
cg15573998 0.001139278 3.52E−05 RA 2 Body NRXN1
cg16012388 0.001186516 5.35E−06 RA 10 Body BICC1
cg16397722 0.00119032 9.50E−06 RA 17 Body TP53
cg20556304 0.001192582 3.94E−11 RA 6
cg25173129 0.00134302 2.51E−07 Healthy 17 TSS1500 EPX
cg01928104 0.001384944 3.10E−06 RA 14 TSS1500 SNORD114-7
cg06734169 0.001534366 4.20E−07 RA 3 5′UTR LRRFIP2
cg04845047 0.00156418 4.88E−05 RA 13
cg26788916 0.001792861 7.32E−05 RA 20
cg00340024 0.001861004 3.01E−05 RA 1
cg08306614 0.001980509 1.42E−05 RA 7 3′UTR NUDCD3
cg19929189 0.001981039 3.59E−09 RA 6
P(tt) t-statistic p value, P(BT) Bartlett’s test p value, Chr chromosome
Fig. 3 Feature enrichment for RA-associated differentially variable positions which are hypervariable in healthy and RA-affected twins respectively.
Differentially variable positions which are hypervariable in the healthy twins were enriched in CpG island shelves and non-CpG island-associated
regions, and in the bodies of genes. Meanwhile, differentially variable positions enriched in RA-affected twins were enriched in 3′UTRs of genes,
gene bodies and non-CpG island-associated regions
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that the DMPs, which are found to be consistently differ-
entially methylated across comparison groups in the ana-
lysis of unrelated individuals, may overlap with the
differentially variable methylation signature identified in
the current study. To test this, we overlapped the DMPs
from the largest EWAS of RA to date with the DVPs iden-
tified in the current study, to assess if alternative study de-
signs and approaches had identified common epigenetic
variants.
The previous study was performed in 691 unrelated
individuals (n = 354 RA cases and 337 unrelated con-
trols) and identified 51,476 DMPs which were putatively
associated with RA, achieving a p < 0.05 following Bon-
ferroni correction [7]. Of the 1171 DVPs identified in
the current study, 132 overlapped with DMPs identified
in the unrelated RA EWAS. Of these, 123 DVPs were
hypervariable in the RA-affected twins in the current
study. In pathway analysis of these overlapping epigen-
etic variants, one of the top ranked pathways was associ-
ated with low-density lipoprotein receptor activity (p =
0.003), which associates closely with the protein pro-
duced by the LRPAP1 gene, the methylation of which
was recently reported as a potential biomarker of
anti-TNF treatment response in RA patients [38].
Overlap with type 1 diabetes-associated DVPs
Genetic susceptibility loci identified in RA have also been
found to confer risk for other autoimmune disorders. RA
and T1D are both common autoimmune diseases with
many characteristics in common, and it is possible that
similarities in epigenetic profile between the two disorders
may provide insight to the development of autoimmune
diseases in general. To test whether epigenetic variants
have commonality across different autoimmune disorders,
we tested for overlap between the RA-associated DVPs
identified in the current study and a set of DVPs recently
identified in a T1D twin study.
A recent study of DNA methylation in T1D-discordant
monozygotic twins (n = 52 twin pairs) identified 16,915
unique DVPs that were hypervariable in T1D across three
cell types. Overlap analysis of the genes associated with
these probes identified 496 genes that are associated with
both RA-DVPs and T1D-DVPs, which is more than ex-
pected by chance (p = 1.6E−29), measured using the phy-
per test for hypergeometric distribution. An overlap
analysis of methylation probe IDs identified 69 specific
probes that overlap between RA-associated DVPs and
T1D-associated DVPs. Permutation testing with 10,000 it-
erations indicated this overlap is more than expected by
chance (p = 0.001). Pathway analysis of these probes iden-
tified many immune-related pathways including a pathway
involved in NF-KB cascade modulation, a process that is
important in inflammation and immune responses. Many
of the top-ranked pathways identified were related to
embryonic development, including neural, embryonic and
epithelial tube formation. The overlapping probes were
enriched in 3′UTR and intergenic regions (Additional file 1:
Figure S4).
Assessment of methylation variability signature in an
independent healthy cohort
The DVP signature identified in RA-discordant twins was
tested in an independent cohort of healthy individuals from
the BIOS cohort [27] to assess if the methylation variability
signature was specific to RA or can also be detected in the
general population. Variance and range statistics were gen-
erated for each DVP for three comparison groups (RA
co-twins, healthy co-twins and healthy BIOS individuals).
The aggregated variance and range statistics for the sites
were then plotted to compare distribution across the three
groups, split by direction of variability. The DVPs which
were hypervariable (n = 763) in RA-affected twins had a
lower variance and a lower range of methylation values in
both healthy twins and the BIOS healthy cohort when com-
pared with RA-affected twins (Fig. 4). The DVPs that were
hypervariable (n = 408) in the healthy co-twins were also
found to have the same trend when compared with the
BIOS cohort, with larger variance and range in the healthy
co-twin and BIOS groups than in the RA-affected group
(Additional file 1: Figure S5).
Discussion
In the largest study of DNA methylation in RA-discordant
MZ twins performed to date, we have identified a signifi-
cant differential variability signature in RA. Differentially
methylated positions were not identified following adjust-
ment for multiple testing in 79 pairs of disease-discordant
twins. The identification of a differentially variable signa-
ture in the absence of a differentially methylated signature
supports the recent findings of an EWAS of T1D-discordant
monozygotic twins, which identified 10,548 DVPs in B cells,
4314 in T cells and 6508 in monocytes [15]. While the T1D
study had a smaller sample size (n= 52 T1D-discordant twin
pairs), it had increased power to detect methylation differ-
ences due to the use of individual cell types. A limitation of
the current study is that it was performed in whole blood,
making it more difficult to identify subtle methylation differ-
ences. However, cell estimates were imputed from the
methylation data using a reference-based statistical algorithm
[24] indicating that there were no significant differences in
proportions of cells tested. The overlap of the RA-associated
DVPs with T1D-associated DVPs identified in individual cell
types is interesting as it indicates that at least a subset of
DVPs identified in individual cell types can also be identified
using whole blood. Another limitation of the study is that
the samples were sourced from two cohorts, which inevitably
confers a batch effect in the data. However, as each
RA-affected individual is matched with their unaffected
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co-twin from the same study, the effect of this on the ana-
lysis is negligible. While the biological implications of DVPs
are not yet fully understood, such DVPs have been found to
be temporally stable over 5 years in T1D [15]. Further longi-
tudinal studies are required to assess if this is the case in RA.
It is also important to consider that the methylation variabil-
ity detected may reflect either cause or consequence of the
disease, which warrants further investigation into the tem-
poral origins and functional consequences of this methyla-
tion variability signature.
RA-associated DVPs were enriched in pathways in-
volved in the regulation of response to stress, including
stress-activated kinase signalling cascades. While these
pathway associations are based on bioinformatics analysis
of methylation data, they have intriguing links to inflam-
matory pathways which warrant further functional investi-
gation in RA. For example, stress kinases have previously
been found to be induced by pro-inflammatory cytokines
in RA, and the stress-activated protein kinase pathway has
been shown to be active in RA synovium, while not being
active in the synovium of patients with osteoarthritis [39].
These findings indicate that the inflammatory component
of RA could potentially induce the observed variability of
DNA methylation in stress response pathways. The vari-
ability of DNA methylation in stress response-regulating
pathways might reflect the adaptation of these cells to
stress-inducing conditions which are present in RA, such
as increased levels of cytokines and induction of oxidative
stress. These findings have lead us to propose a new work-
ing model of the development of RA (Fig. 5) illustrating
the potential role of DNA methylation variability and
stress response pathways in the aetiology of disease.
The RA-associated DVPs were also enriched in a path-
way controlling K63 protein ubiquitination. The ubiqui-
tination of K63 acts as a modulator of oxidative stress
response, which induces thioredoxin, a catalyst found to
be overexpressed in RA patients [40]. Thioredoxin has
also been found to activate the NF-KB pathway [41],
which we observed to be enriched with DVPs in both
RA- and T1D-affected twins.
Disease-associated epigenetic alterations have been
hypothesised to be caused by chronic cellular stress, which
can be induced by inflammation [42]. Accumulating evi-
dence indicates that these stress-induced changes in the
epigenetic landscape cause changes in cellular state and
function, which can contribute to disease development.
The enrichment of RA-associated DVPs in stress
response-related pathways supports this hypothesis and
suggests that, as well as altering cellular state, such epi-
genetic changes are also modulating the response to cellu-
lar and oxidative stress. This could be perpetuating the
disease phenotype by repressing cellular stress response
mechanisms in cells exposed to inflammation.
Meta-analysis of two other autoimmune EWAS studies
identified a set of 496 genes that contain DVPs in both
RA and T1D. This provides an intriguing possibility of
common pathways in which DNA methylation is hyper-
variable in autoimmune disorders. These may provide
novel pathways for treatment, and generate hypotheses re-
garding autoimmune disease pathogenesis. For example,
Fig. 4 Variance and range for DVPs which were hypervariable in RA co-twins. Variance and range were calculated for each of the 763 DVPs found to
be hypervariable in RA co-twins, plotted for three comparison groups; RA co-twins, healthy co-twins and an independent cohort of healthy individuals
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one of the overlapping genes was PRKCZ, which was also
the gene containing the second most differentially methyl-
ated probe in the current study. This gene was previously
found to be hypermethylated in RA fibroblast-like syno-
viocyte cells [43] and has also been found to be hypo-
methylated in T1D monocytes and whole blood [44]. The
largest RA EWAS of unrelated individuals identified 132
DMPs which were found to overlap with the DVPs identi-
fied in the current study. Pathway analysis of these sites
identified a pathway associated with the LRPAP1 gene,
which was recently identified as a biomarker of treatment
response in RA [38]. This overlapping signature of differ-
ential variability on methylation in two autoimmune
diseases suggests that epigenetics plays a role in auto-
immunity, which warrants further investigation in func-
tional studies to elucidate its’ role in autoimmune disease
pathogenesis.
Conclusions
In a genome-wide investigation of DNA methylation in
RA-discordant MZ twins, we have identified differential
variability of DNA methylation, but no statistically sig-
nificant DMPs. This supports the findings of a recent
investigation of DNA methylation in T1D-discordant
monozygotic twins, which identified a disease-associated
DVP signature in the absence of a substantial DMP signa-
ture. Due to the influence of genetic components in estab-
lishing DNA methylation [45], our study indicates that
differentially methylated positions that have previously
been associated with RA [6–10] do not replicate in co-
horts of disease-discordant monozygotic twins, which are
less confounded by genetic heterogeneity. Furthermore,
we identified a series of stress response-associated path-
ways which may potentially play a role in RA aetiology.
These pathways interact with pro-inflammatory cytokines
known to be integral in the development of RA, thus are
of direct relevance to RA pathogenesis and could provide
potential targets for RA therapy development. The role of
stress response in RA pathology warrants further investi-
gation to determine the downstream functional effects of
this DNA methylation variability and to further character-
ise the role of variability of DNA methylation in complex
diseases such as RA.
Fig. 5 Prevailing and suggested models of RA disease development. The current model of RA aetiology primarily involves the contribution of genetic and
non-genetic factors including triggers such as infection, which mediate an immune response and ultimately contribute to the clinical manifestation of RA. Our
suggested model of RA development incorporates the potential role of DNA methylation alongside the contributing factors of oxidative and cellular stress
Webster et al. Genome Medicine  (2018) 10:64 Page 10 of 12
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